{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:00:05Z","timestamp":1789556405088,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.msard.2025.106578","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T12:20:10Z","timestamp":1749558010000},"page":"106578","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Safety and Efficacy of Cladribine in Patients Discontinuing Fingolimod Due to Elevated Transaminase Levels: The FinClad Study"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4418-7906","authenticated-orcid":false,"given":"Meryem Tuba","family":"S\u00f6nmez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2541-7107","authenticated-orcid":false,"given":"Mehmet Fatih","family":"Yetkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0438-4502","authenticated-orcid":false,"given":"Duygu Arslan","family":"Mehdiyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0469-0064","authenticated-orcid":false,"given":"Mesrure","family":"K\u00f6seo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6469-5185","authenticated-orcid":false,"given":"Semra","family":"Mungan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-6223","authenticated-orcid":false,"given":"Nilufer","family":"Kale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3586-9115","authenticated-orcid":false,"given":"Murat","family":"Terzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9747-5285","authenticated-orcid":false,"given":"Abdulkadir","family":"Tun\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0264-7284","authenticated-orcid":false,"given":"Emine Rabia","family":"Ko\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8048-6845","authenticated-orcid":false,"given":"Sedat","family":"\u015een","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2227-4104","authenticated-orcid":false,"given":"Serkan","family":"Ozben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir Kurtulu\u015f","family":"Yolda\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4635-2880","authenticated-orcid":false,"given":"Vedat","family":"\u00c7ilingir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3101-4742","authenticated-orcid":false,"given":"Dilcan","family":"Kotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durdane","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8772-6087","authenticated-orcid":false,"given":"Fatma Kurtulu\u015f","family":"Ayd\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2580-9650","authenticated-orcid":false,"given":"Belgin","family":"Ko\u00e7er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6788-6107","authenticated-orcid":false,"given":"Mehmet","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"\u00c7am","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9422-5723","authenticated-orcid":false,"given":"P\u0131nar","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2104-6003","authenticated-orcid":false,"given":"Yasemin Ekmekyapar","family":"F\u0131rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5899-1180","authenticated-orcid":false,"given":"Sami","family":"\u00d6merhoca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4893-7807","authenticated-orcid":false,"given":"Merve Bahar","family":"Ercan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Skuljec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refik","family":"Pul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106578_bib0001","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s40120-019-00160-9","article-title":"Fingolimod Rebound: a review of the clinical experience and management considerations","volume":"8","author":"Barry","year":"2019","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106578_bib0002","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40263-021-00842-9","article-title":"The disease-modifying therapies of relapsing-remitting multiple sclerosis and liver injury: a narrative review","volume":"35","author":"Biolato","year":"2021","journal-title":"CNS Drugs."},{"key":"10.1016\/j.msard.2025.106578_bib0003","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1080\/03007995.2023.2256220","article-title":"The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis","volume":"39","author":"Butzkueven","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.msard.2025.106578_bib0004","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/03007995.2022.2059977","article-title":"The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets","volume":"38","author":"Butzkueven","year":"2023","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.msard.2025.106578_bib0005","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s40120-024-00589-7","article-title":"Holistic, long-term management of people with relapsing multiple sclerosis with Cladribine tablets: expert opinion from France","volume":"13","author":"Ciron","year":"2024","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106578_bib0006","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s40120-023-00496-3","article-title":"Expert narrative review of the safety of cladribine tablets for the management of relapsing multiple sclerosis","volume":"12","author":"Clavelou","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2025.106578_bib0007","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1177\/13524585241272938","article-title":"Aging is associated with reduced inflammatory disease activity independent of disease duration in relapsing multiple sclerosis trial populations","volume":"30","author":"Coerver","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106578_bib0008","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s40263-024-01074-3","article-title":"Magnetic resonance imaging evidence supporting the efficacy of cladribine tablets in the treatment of relapsing-remitting multiple sclerosis","volume":"38","author":"Cortese","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.msard.2025.106578_bib0009","first-page":"9","article-title":"Early reduction of MRI activity during 6 months of treatment with cladribine tablets for highly active relapsing multiple sclerosis: MAGNIFY-MS","author":"de Stefano","year":"2022","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2025.106578_bib0011","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00415-021-10708-1","article-title":"Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration","volume":"269","author":"Ferraro","year":"2022","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106578_bib0012","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/ene.13694","article-title":"Clinical activity after fingolimod cessation: disease reactivation or rebound?","volume":"25","author":"Frau","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106578_bib0013","first-page":"88","article-title":"Effects of fingolimod treatments on alanine transaminase and aspartate transaminase levels in patients with multiple sclerosis","volume":"12","author":"Joni","year":"2020","journal-title":"Int. J. Physiol. Pathophysiol. Pharmacol."},{"key":"10.1016\/j.msard.2025.106578_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102065","article-title":"Liver injury after methylprednisolone pulse therapy in multiple sclerosis is usually due to idiosyncratic drug-induced toxicity rather than autoimmune hepatitis","volume":"42","author":"Kimura","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106578_bib0015","doi-asserted-by":"crossref","first-page":"e1334","DOI":"10.1212\/WNL.0000000000012603","article-title":"Association of age with contrast-enhancing lesions across the Multiple sclerosis disease spectrum","volume":"97","author":"Koch","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106578_bib0017","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1212\/WNL.0000000000202998","article-title":"Updated post-approval safety of cladribine tablets in the treatment of multiple sclerosis, with particular reference to liver safety (P7-3.010)","volume":"100","author":"Leist","year":"2023","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106578_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105134","article-title":"Frequency and risk factors of rebound after fingolimod discontinuation - A retrospective study","volume":"81","author":"Maunula","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106578_bib0020","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208006","article-title":"Adverse events associated with disease-modifying drugs for multiple sclerosis: a multiregional population-based study","volume":"102","author":"Ng","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106578_bib36","doi-asserted-by":"crossref","first-page":"103812","DOI":"10.1016\/j.msard.2022.103812","article-title":"Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis","volume":"62","author":"Nygaard","year":"2022","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106578_bib0021","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106578_bib0022","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106578_bib0023","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2023-000481","article-title":"Oral cladribine treatment and idiosyncratic drug-induced liver injury in multiple sclerosis","volume":"5","author":"Rakers","year":"2023","journal-title":"BMJ Neurol. Open"},{"key":"10.1016\/j.msard.2025.106578_bib0025","doi-asserted-by":"crossref","first-page":"e1926","DOI":"10.1212\/WNL.0000000000201029","article-title":"Disease reactivation after cessation of Disease-modifying therapy in patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Roos","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106578_bib0026","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1177\/1352458519866613","article-title":"Age-related decreases in relapses among adults with relapsing-onset multiple sclerosis","volume":"26","author":"Schwehr","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106578_bib0028","doi-asserted-by":"crossref","DOI":"10.1111\/ene.16289","article-title":"Real-world persistence of multiple sclerosis disease-modifying therapies","volume":"31","author":"Tallantyre","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106578_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105757","article-title":"Recurring disease activity in relapsing remitting multiple sclerosis: the multicenter RDA-RMS study","volume":"88","author":"Tun\u00e7","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106578_bib0030","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3390\/ph16081071","article-title":"Hepatobiliary adverse reactions during treatment with cladribine: analysis of data from the european spontaneous reporting system","volume":"16","author":"Veli\u0219cu","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.msard.2025.106578_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105435","article-title":"Consensus recommendations for diagnosis and treatment of Multiple sclerosis: 2023 revision of the MENACTRIMS guidelines","volume":"83","author":"Yamout","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106578_bib35","first-page":"1330","article-title":"Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis","volume":"93","author":"Zhu","year":"2022","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106578_fur1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40261-022-01129-7","article-title":"Multiple sclerosis relapses following cessation of Fingolimod","volume":"42","author":"Malpas","year":"2022","journal-title":"Clin. Drug. Investig."},{"key":"10.1016\/j.msard.2025.106578_fur2","doi-asserted-by":"crossref","first-page":"105052","DOI":"10.1016\/j.msard.2023.105052","article-title":"Real-world treatment patterns and effectiveness of cladribine tablets in patients with relapsing forms of multiple sclerosis in the United States","volume":"79","author":"Song","year":"2023","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003207?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003207?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:42:08Z","timestamp":1755650528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825003207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":30,"alternative-id":["S2211034825003207"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106578","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Cladribine in Patients Discontinuing Fingolimod Due to Elevated Transaminase Levels: The FinClad Study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106578","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106578"}}